Amicus Therapeutics Inc
NASDAQ:FOLD
Intrinsic Value
Amicus Therapeutics, Inc. operates as a biotechnology company. [ Read More ]
The intrinsic value of one FOLD stock under the Base Case scenario is 19.96 USD. Compared to the current market price of 10.33 USD, Amicus Therapeutics Inc is Undervalued by 48%.
Valuation Backtest
Amicus Therapeutics Inc
Run backtest to discover the historical profit from buying and selling FOLD stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Amicus Therapeutics Inc
Current Assets | 483.1m |
Cash & Short-Term Investments | 286.2m |
Receivables | 87.6m |
Other Current Assets | 109.2m |
Non-Current Assets | 294.8m |
PP&E | 58m |
Intangibles | 218.3m |
Other Non-Current Assets | 18.6m |
Current Liabilities | 167.7m |
Accounts Payable | 15.1m |
Accrued Liabilities | 152.6m |
Non-Current Liabilities | 450m |
Long-Term Debt | 387.9m |
Other Non-Current Liabilities | 62.2m |
Earnings Waterfall
Amicus Therapeutics Inc
Revenue
|
399.4m
USD
|
Cost of Revenue
|
-37.3m
USD
|
Gross Profit
|
362m
USD
|
Operating Expenses
|
-438.1m
USD
|
Operating Income
|
-76.1m
USD
|
Other Expenses
|
-75.5m
USD
|
Net Income
|
-151.6m
USD
|
Free Cash Flow Analysis
Amicus Therapeutics Inc
What is Free Cash Flow?
FOLD Profitability Score
Profitability Due Diligence
Amicus Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Amicus Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
FOLD Solvency Score
Solvency Due Diligence
Amicus Therapeutics Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Score
Amicus Therapeutics Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FOLD Price Targets Summary
Amicus Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for FOLD is 19.13 USD with a low forecast of 14.14 USD and a high forecast of 23.1 USD.
Ownership
FOLD Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
FOLD Price
Amicus Therapeutics Inc
Average Annual Return | 14.36% |
Standard Deviation of Annual Returns | 77.8% |
Max Drawdown | -75% |
Market Capitalization | 3B USD |
Shares Outstanding | 295 383 008 |
Percentage of Shares Shorted | 11.05% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Amicus Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 496 full-time employees. The company went IPO on 2007-05-31. The firm's portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.
Contact
IPO
Employees
Officers
The intrinsic value of one FOLD stock under the Base Case scenario is 19.96 USD.
Compared to the current market price of 10.33 USD, Amicus Therapeutics Inc is Undervalued by 48%.